{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-039875","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.990367+00:00","generated_at":"2026-06-22T08:13:39.711948+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rocket Pharma Q3 net loss $57.8M; cash $306.5M; Renovacor acquisition, LAD-I/FA filings on track","bullets":["Net loss $57.8M ($0.87/sh) vs $50.1M in Q3 2021; R&D expenses $43.4M, G&A $15.1M.","Cash, equivalents and investments $306.5M; after $108.2M equity offering, operational runway into 2H 2024.","Announced all-stock acquisition of Renovacor (implied ~$2.60/sh) to extend AAV cardiac gene therapy; expected close Q1 2023.","Danon Disease Phase 1 data positive; FDA feedback on Phase 2 pivotal design anticipated Q4 2022.","LAD-I regulatory filing expected 1H 2023, FA filing 2H 2023; PKD Phase 1 enrollment complete, Phase 2 pivotal in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-039875","json":"https://secwatch.observer/filing/0001140361-22-039875.json","markdown":"https://secwatch.observer/filing/0001140361-22-039875.md","text":"https://secwatch.observer/filing/0001140361-22-039875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036122039875/0001140361-22-039875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036122039875/brhc10043730_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:13:39.711948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"921f28618ff4b55ebcd26c76958e8e6c37c7c328","claim":"ROCKET PHARMACEUTICALS, INC. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Rocket Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036122039875/0001140361-22-039875-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}